Trial Profile
The Effect of Dipeptidyl Peptidase IV Inhibition on Growth Hormone-Mediated Vasodilation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pegvisomant (Primary) ; Sitagliptin (Primary)
- Indications Obesity; Prediabetic state
- Focus Pharmacodynamics
- 27 Jun 2017 Status changed from active, no longer recruiting to completed.
- 15 Feb 2017 Planned End Date changed from 1 Jan 2017 to 1 May 2017.
- 15 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 May 2017.